Interventional Oncology Devices Market worth US$ 4.2 Billion 2025 with a CAGR of 9.20%

The report "Global Interventional Oncology Devices Market, By Product (Embolization Devices, Ablation Devices, and Support Devices), By Procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, and Transcatheter Arterial Embolization/Bland Embolization), By Cancer (Liver Cancer, Lung Cancer, Bone Cancer, and Kidney Cancer), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030".

Growing incidence and increasing prevalence of cancer globally among individuals is the major factor driving the growth of the global interventional oncology devices. According to data published by WHO, cancer acts as the second leading cause of death worldwide and accounted for 9.6 million deaths in 2018. Approximately 70% of deaths occur in low- and middle-income countries from cancer. Also, high preference for minimally invasive surgical procedures, favourable reimbursement scenario for interventional oncology treatment in developed countries, availability of government and private funding, and others. These factors are also expected to boost the growth of the global market over the forecast period. Nevertheless, increasing merger and acquisitions among the industry players along with product launches are expected to create lucrative growth opportunities for the target market over the forecast period.

Key Highlights:

• In April 2018, Varian declared the launch of their new version of Velocity cancer imaging software. The software includes Rapidsphere, a module for Y90 Selective Internal Radiation Therapy (SIRT) dosimetry analysis. It helps in understanding the tumor better and normal- tumor toxicity of individual patient.
• In December 2017, Becton, Dickinson and Company, a leading global medical technology company, has proclaimed that it has completed the acquisition of C. R. Bard, Inc. The acquisition involves creating a new health care industry leader with approximately US$16 billion in annualized revenue.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3996

Key Market Insights from the report:

The global interventional oncology devices market accounted for US$ 4.2 billion in 2025 and is projected to register a moderate CAGR over the forecast period. The market report has been segmented based on product, procedure, cancer, and region.

• By product, embolization devices segment commanded the highest share of the global interventional oncology market in 2018 owing to their wide usage with high specificity, sensitivity, and accuracy towards characterization and detection of tumors.
• By procedure, the target market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization, transcatheter arterial radioembolization/selective internal radiation therapy, and transcatheter arterial embolization/bland embolization
• By cancer, liver cancer segment estimated for the largest share of the global market in 2018 primarily due to growing prevalence of the disease and related mortality coupled with the availability of a wide range of ablation and embolization products across the globe for liver cancer treatment.
• By region, in 2018, North America accounted for the highest share of the global interventional oncology market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. However, Asia-Pacific is expected to be the fastest-growing regional market owing to growing government focus on the healthcare sector and accelerated economic growth of many countries in this region.

The prominent player operating in the global interventional oncology devices market includes AngioDynamics Inc., Becton, Dickinson and Company, Boston Scientific Corporation, BTG PLC, HealthTronics Inc., Medtronic PLC, Sirtex Medical Ltd., Merit Medical Systems Inc., and Terumo Corporation.